New breast cancer drug Datroway extends survival
Datroway, a new medicine, has helped people with advanced triple-negative breast cancer (TNBC) live longer—especially those who can't get immunotherapy.
Results from a major 2024 study show this is the first real survival boost for these patients.
Patients lived about 5 months longer
In the TROPION-Breast02 trial, Datroway patients lived about 5 months longer than those on regular chemotherapy (23.7 vs 18.7 months).
It also kept the cancer from getting worse for longer, hinting at a possible shift in how doctors treat TNBC.
Drug delivered with less toxicity
Datroway delivers a cytotoxic payload straight to tumor cells with less toxicity, thanks to Daiichi Sankyo's DXd technology.
People stayed on it twice as long as chemo, without more severe side effects or new safety issues.
Datroway joins Enhertu in modern treatment
After its US approval earlier in 2024 for certain breast and lung cancer types, Datroway now joins Enhertu (another DXd-based drug) as part of modern breast cancer treatment.
According to company leadership, together these drugs could potentially help around 90% of people with metastatic breast cancer and set new standards worldwide.